North America Chemotherapy Induced Peripheral Neuropathy Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. North America Chemotherapy Induced Peripheral Neuropathy Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. North America Chemotherapy Induced Peripheral Neuropathy Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. North America Chemotherapy Induced Peripheral Neuropathy Market Regional Analysis

6.2 North America Chemotherapy Induced Peripheral Neuropathy Market Revenue 2019-2028 (US$ Billion)

6.3 North America Chemotherapy Induced Peripheral Neuropathy Market Forecast Analysis

7. North America Chemotherapy Induced Peripheral Neuropathy Market Analysis – by Drug Class

7.1 Steroids

7.1.1 Overview
7.1.2 Steroids: North America Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast, 2019-2028 (US$ Billion)

7.2 Antidepressants

7.2.1 Overview
7.2.2 Antidepressants: North America Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast, 2019-2028 (US$ Billion)

7.3 Ant seizure

7.3.1 Overview
7.3.2 Ant seizure: North America Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast, 2019-2028 (US$ Billion)

7.4 Narcotics

7.4.1 Overview
7.4.2 Narcotics: North America Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast, 2019-2028 (US$ Billion)

8. North America Chemotherapy Induced Peripheral Neuropathy Market Analysis – by Distribution Channel

8.1 Retail Pharmacy

8.1.1 Overview
8.1.2 Retail Pharmacy: North America Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast, 2019-2028 (US$ Billion)

8.2 Hospital Pharmacy

8.2.1 Overview
8.2.2 Hospital Pharmacy: North America Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast, 2019-2028 (US$ Billion)

8.3 Online Pharmacy

8.3.1 Overview
8.3.2 Online Pharmacy : North America Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast, 2019-2028 (US$ Billion)

9. North America Chemotherapy Induced Peripheral Neuropathy Market – North America Analysis

9.1 Overview

9.2 North America

9.2.1 North America Chemotherapy Induced Peripheral Neuropathy Market Breakdown, by Key Country, 2022 and 2028 (%)
9.2.1.1 North America Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast Analysis – by Country
9.2.1.1 US: North America Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Billion)

9.2.1.1.1 US: North America Chemotherapy Induced Peripheral Neuropathy Market Breakdown, by Drug Class
9.2.1.1.2 US: North America Chemotherapy Induced Peripheral Neuropathy Market Breakdown, by Distribution Channel

9.2.1.2 Canada: North America Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Billion)

9.2.1.2.1 Canada: North America Chemotherapy Induced Peripheral Neuropathy Market Breakdown, by Drug Class
9.2.1.2.2 Canada: North America Chemotherapy Induced Peripheral Neuropathy Market Breakdown, by Distribution Channel

9.2.1.3 Mexico : North America Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Billion)

9.2.1.3.1 Mexico : North America Chemotherapy Induced Peripheral Neuropathy Market Breakdown, by Drug Class
9.2.1.3.2 Mexico : North America Chemotherapy Induced Peripheral Neuropathy Market Breakdown, by Distribution Channel

10. Competitive Landscape

10.1 Heat Map Analysis

10.2 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview

11.2 Market Initiative

11.3 Partnerships and Collaborations

11.4 Other Developments

12. Company Profiles

12.1 REGENACY PHARMACEUTICALS, INC.

12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments

12.2 Asahi Kasei Pharma Corporation

12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments

12.3 MAKScientific, LLC

12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments

12.4 WEX Pharmaceuticals Inc.

12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments

12.5 Sova Pharmaceuticals, Inc.

12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments

12.6 Kineta, Inc.

12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments

12.7 Aptinyx Inc.

12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments

12.8 Apexian Pharmaceuticals, Inc.

12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments

12.9 WinSanTor, Inc.

12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments

13. Appendix

13.1 About Business Market Insights

13.2 List of Abbreviations

North America Chemotherapy Induced Peripheral Neuropathy Market

Analysis – Drug Class (Steroids, Antidepressants, Ant seizure, and Narcotics) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy)